Literature DB >> 22817875

Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein.

Ingrid Dieset1, Sigrun Hope, Thor Ueland, Thomas Bjella, Ingrid Agartz, Ingrid Melle, Pål Aukrust, Jan-Ivar Røssberg, Ole A Andreassen.   

Abstract

OBJECTIVE: Severe mental disorder and cardiovascular disease (CVD) are often associated, and inflammation is implicated in both disorders. We investigated whether there is a relationship between CVD risk factors and inflammation in schizophrenia or bipolar disorder, and if second generation antipsychotics (SGA) interact.
METHODS: We included 361 patients in a naturalistic cross-sectional study, 235 subjects on current SGA treatment and 126 subjects not treated with SGA as controls. Cardiovascular parameters were measured and current medication recorded. Fasting plasma levels of the following cytokines were measured: high sensitivity CRP (hsCRP), soluble tumor necrosis factor receptor 1 (sTNF-R1), osteoprotegerin (OPG), soluble CD40 ligand (sCD40L), interleukin-1 receptor antagonist (IL-1Ra), von Willebrand factor (vWf) and interleukin-6 (IL-6).
RESULTS: In this relatively young sample of patients with a mean age of 33.3years, the following CVD risk factors were associated with elevated inflammation markers after adjusting for confounders: BMI, triglycerides and glucose with hsCRP (p=0.041-0.001), HDL-cholesterol and triglycerides with sTNF-R1 (p=0.009-0.001) and triglycerides with vWf (p=0.004). In patients treated with SGA, elevated hsCRP was significantly associated with high BMI (p=0.012), and with high glucose levels (p=0.003).
CONCLUSION: Several CVD risk factors are associated with elevated levels of inflammation markers in young patients with severe mental illness. The interaction between SGA and CVD risk factors on hsCRP levels might indicate a specific inflammatory activation related to SGA induced overweight and hyperglycemia. This suggests that hsCRP could be a valuable marker for future cardiovascular events, particularly in patients treated with SGA.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22817875     DOI: 10.1016/j.schres.2012.06.040

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  13 in total

1.  Correlations between Body Mass Index, Plasma High-Sensitivity C-Reactive Protein and Lipids in Patients with Schizophrenia.

Authors:  Ted Boozalis; Sridevi Devaraj; Olaoluwa O Okusaga
Journal:  Psychiatr Q       Date:  2019-03

2.  Modulating Specific Pathways In Vitro to Understand the Synaptic Dysfunction of Schizophrenia.

Authors:  Verônica M Saia-Cereda
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

3.  The in vitro effects of sodium salicylate on von Willebrand factor and C-reactive protein production by endothelial cells.

Authors:  Minoo Shahidi; Mahmood Barati; Parisa Hayat; Behnaz Tavasoli; Masoomeh Bakhshayesh
Journal:  Inflammopharmacology       Date:  2014-07-24       Impact factor: 4.473

4.  Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia?

Authors:  Jamie Joseph; Colin Depp; Pei-An B Shih; Kristen S Cadenhead; Geert Schmid-Schönbein
Journal:  Front Neurosci       Date:  2017-03-27       Impact factor: 4.677

Review 5.  Bipolar Spectrum Disorders in Male Youth: The Interplay between Symptom Severity, Inflammation, Steroid Secretion, and Body Composition.

Authors:  Andreas Walther; Marlene Penz; Daniela Ijacic; Timothy R Rice
Journal:  Front Psychiatry       Date:  2017-10-18       Impact factor: 4.157

6.  Immunomodulatory Effects of Probiotic Supplementation in Schizophrenia Patients: A Randomized, Placebo-Controlled Trial.

Authors:  Jakub Tomasik; Robert H Yolken; Sabine Bahn; Faith B Dickerson
Journal:  Biomark Insights       Date:  2015-06-01

Review 7.  A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation.

Authors:  Monica Aas; Paola Dazzan; Valeria Mondelli; Ingrid Melle; Robin M Murray; Carmine M Pariante
Journal:  Front Psychiatry       Date:  2014-01-08       Impact factor: 5.435

Review 8.  Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions.

Authors:  Petter Andreas Ringen; John A Engh; Astrid B Birkenaes; Ingrid Dieset; Ole A Andreassen
Journal:  Front Psychiatry       Date:  2014-09-26       Impact factor: 4.157

9.  The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis.

Authors:  Erik Johnsen; Farivar Fathian; Rune A Kroken; Vidar M Steen; Hugo A Jørgensen; Rolf Gjestad; Else-Marie Løberg
Journal:  BMC Psychiatry       Date:  2016-03-14       Impact factor: 3.630

10.  Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study.

Authors:  Dag K Solberg; Håvard Bentsen; Helge Refsum; Ole A Andreassen
Journal:  BMC Psychiatry       Date:  2016-08-25       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.